S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Triquetra Health Targets Hair Thinning With Single-Active Supplement

Austin-based Triquetra Health has released Folura, a once-daily hair supplement designed to address thinning at the follicle rather than the strand. By utilizing a precise 160 mg dose of Serevelle saw palmetto extract, the company aims to move away from traditional multi-ingredient blends toward clinically backed, single-active formulations.

Triquetra Health Targets Hair Thinning With Single-Active Supplement
Photo: Bio & News

Most hair supplements rely on long lists of vitamins like biotin or collagen to nourish existing hair. Triquetra Health argues that this approach ignores the root cause of thinning, which occurs deeper within the follicle due to hormonal shifts that shorten the growth cycle. Folura shifts this focus by centering on Serevelle, a standardized saw palmetto extract that supports DHT balance and the hair's natural growth phase.

The effectiveness of this specific dose was highlighted in a six-month, double-blind, placebo-controlled trial published in the Journal of Cosmetic Dermatology. Participants receiving the 160 mg dose of the extract demonstrated a 306% greater total hair density compared to the placebo group. The company emphasizes full label transparency, disclosing the exact amounts of Serevelle and its companion botanical, cold-pressed pumpkin seed oil, without the use of proprietary blends. The product is now available for purchase on Amazon and the company’s website.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!